Ftse Mib
34.761,97
0,79%
DAX
18.774,71
0,43%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
69.393,19
1,29%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Solid Biosciences Inc (SLDB) Solid Biosciences Inc (SLDB) Notizie

SLDB

Solid Biosciences (SLDB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SLDB
DataOraFonteTitoloSimboloCompagnia
20/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SLDBSolid Biosciences Inc
15/05/202414:26Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SLDBSolid Biosciences Inc
15/05/202413:52GlobeNewswire Inc.Solid Biosciences Provides First Quarter 2024 Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
15/05/202413:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLDBSolid Biosciences Inc
07/05/202413:00GlobeNewswire Inc.Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual MeetingNASDAQ:SLDBSolid Biosciences Inc
07/05/202400:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
02/05/202422:05GlobeNewswire Inc.Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLDBSolid Biosciences Inc
01/04/202413:45GlobeNewswire Inc.Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
27/03/202412:00GlobeNewswire Inc.Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy SymposiumNASDAQ:SLDBSolid Biosciences Inc
13/03/202412:44GlobeNewswire Inc.Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
07/03/202413:00GlobeNewswire Inc.Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHDNASDAQ:SLDBSolid Biosciences Inc
06/03/202414:00GlobeNewswire Inc.Solid Biosciences to Participate at Upcoming Investor ConferencesNASDAQ:SLDBSolid Biosciences Inc
30/01/202422:09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SLDBSolid Biosciences Inc
20/01/202401:23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/01/202414:50Dow Jones NewsSolid Biosciences Gets Orphan Drug Designation for SGT-003NASDAQ:SLDBSolid Biosciences Inc
16/01/202414:00GlobeNewswire Inc.Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
12/01/202423:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SLDBSolid Biosciences Inc
08/01/202413:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLDBSolid Biosciences Inc
08/01/202413:09GlobeNewswire Inc.Solid Biosciences Announces $109 Million Private PlacementNASDAQ:SLDBSolid Biosciences Inc
04/01/202414:00GlobeNewswire Inc.Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SLDBSolid Biosciences Inc
07/12/202316:49Dow Jones NewsSolid Biosciences Shares Jump After FDA Fast-Tracks SGT-0003NASDAQ:SLDBSolid Biosciences Inc
07/12/202314:00GlobeNewswire Inc.Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003NASDAQ:SLDBSolid Biosciences Inc
22/11/202314:00GlobeNewswire Inc.Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:SLDBSolid Biosciences Inc
15/11/202314:51IH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:SLDBSolid Biosciences Inc
14/11/202322:05GlobeNewswire Inc.Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
09/11/202314:00GlobeNewswire Inc.Solid Biosciences to Participate at Jefferies London Healthcare ConferenceNASDAQ:SLDBSolid Biosciences Inc
08/11/202322:17GlobeNewswire Inc.Solid Biosciences Provides Third Quarter Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
02/10/202314:00GlobeNewswire Inc.Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical OfficerNASDAQ:SLDBSolid Biosciences Inc
31/08/202314:00GlobeNewswire Inc.Solid Biosciences to Participate in Citi’s 18th Annual BioPharma ConferenceNASDAQ:SLDBSolid Biosciences Inc
14/08/202322:17GlobeNewswire Inc.Solid Biosciences Provides Second Quarter Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SLDB

La tua Cronologia

BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
TIT
Telecom Italia
BIT
ENI
Eni
BIT
SPM
Saipem
BIT
STMMI
ST Microelectronics
BIT
PRY
Prysmian
BIT
WBD
WeBuild
BIT
TITR
Telecom Italia
BIT
SRG
Snam
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
BIT
TEN
Tenaris
BIT
RACE
Ferrari NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network